AGIO — Agios Pharmaceuticals Share News
0.000.00%
- $2.21bn
- $1.59bn
- $54.03m
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Agios Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Agios Q2 revenue jumps on US commercial launch of AQVESME
Brief: Agios Pharmaceuticals Q2 Product Revenue USD 44.745 Million Vs. IBES Estimate USD 25.5 Million
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. STOCKS ON THE MOVE-Duke Robotics, Tesla, Hasbro
U.S. STOCKS ON THE MOVE-Utz Brands, Tutor Perini, Tripadvisor
U.S. STOCKS ON THE MOVE-3M, Gold Miners, Hasbro
Brief: Agios Provides Update On Phase 2 Trial Of Tebapivat In Sickle Cell Disease
Agios scraps sickle cell treatment after trial shows limited benefit (updated)
Agios falls after scrapping experimental sickle cell disease drug
Agios Pharma to discontinue sickle cell disease treatment development
U.S. STOCKS ON THE MOVE-Vera Therapeutics, Vera Therapeutics, Nvidia
U.S. STOCKS ON THE MOVE-Revolution Medicines, Vivani Medical, Nvidia
U.S. STOCKS ON THE MOVE-Nvidia, Crinetics Pharmaceuticals, Rivian Automotive
U.S. STOCKS ON THE MOVE-Tesla, Nvidia, Rivian
Agios rises as FDA grants priority review to sickle cell disease drug
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco